Insights into the diverse roles of miR-205 in human cancers

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 2, 2014, Pages 577-583

  Orang, Ayla Valinezhad ^a   Safaralizadeh, Reza ^a   Feizi, Mohammad Ali Hosseinpour ^a  

^a UNIVERSITY OF TABRIZ   (Iran)

Author keywords

Biomarker; EMT; MiR 205; miRNA; Oncogene; Tumor suppressor

Indexed keywords

MICRORNA;

GENE EXPRESSION REGULATION; GENETICS; HUMAN; NEOPLASM; PHYSIOLOGY; SHORT SURVEY;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS;

EID: 84894669675     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.2.577     Document Type: Short Survey

References (107)

1. Adachi R, Horiuchi S, Sakurazawa Y, et al (2011). ErbB2 down-regulates microRNA-205 in breast cancer. Biochem Biophys Res Commun, 411, 804-8.
2. American Cancer Society (2007). Cancer facts and figures 2007, Atlanta, Ga, USA.
3. Babak T, Zhang W, Morris Q, Blencowe BJ, Hughes TR (2004). Probing microRNAs with microarrays: tissue specificity and functional inference. RNA, 10, 1813-9.
4. Benjamini Ya, Hochberg Y (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B, 57, 289-300.
5. Bishop JA, Benjamin H, Cholakh H, et al (2010). Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res, 16, 610-9.
6. Blenkiron C, Goldstein LD, Thorne NP, et al (2007). MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol, 8, 214.
7. Blot WJ, Devesa SS, Fraumeni JF Jr (1993). Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA, 270, 1320.
8. Boll K, Reiche K, Kasack K, et al (2013). MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene, 32, 277-85.
9. Boren T, Xiong Y, Hakam A, et al (2008). MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol, 110, 206-15.
10. Cai Y, Yu X, Hu S, Yu J (2009). A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics, 7, 147-54.
11. Calin GA, Sevignani C, Dumitru CD, et al (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A, 101, 2999-3004.
12. Campobasso O, Andrion A, Ribotta M, Ronco G (1993). The value of the 1981 WHO histological classification in inter-observer reproducibility and changing pattern of lung cancer. Int J Cancer, 53, 205-8.
13. Chaffer CL, Weinberg RA (2011). A perspective on cancer cell metastasis. Science, 331, 1559-64.
14. Chang CJ, Hsu CC, Chang CH, et al (2011). Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer. Oncol Rep, 26, 1003-10.
15. Chekulaeva M, Filipowicz W (2009). Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol, 21, 452-60.
16. Childs G, Fazzari M, Kung G, et al (2009). Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol, 174, 736-45.
17. Chung TK, Cheung TH, Huen NY, et al (2009). Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer, 124, 1358-65.
18. Croce CM (2012). 37 Causes and Consequences of microRNA Dysregulation in Cancer. Eur J Cancer, 48, 8-9.
19. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007). FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist, 12, 713-8.
20. Cohn DE, Fabbri M, Valeri N, et al (2010). Comprehensive miRNA profiling of surgically staged endometrial cancer. Am J Obstet Gynecol, 202, 1-8.
21. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, et al (2012). Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. Cell Cycle, 11, 1235-46.
22. Dar AA, Majid S, de Semir D, et al (2011). miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem, 286, 16606-14.
23. Darnell DK, Kaur S, Stanislaw S, et al (2006). MicroRNA expression during chick embryo development. Dev. Dyn, 235, 3156-65.
24. Dip N, Reis ST, Timoszczuk LS, et al (2012). Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile. J Urol, 188, 1951-6.
25. Fabian MR, Sundermeier TR, Sonenberg N (2010). Understanding how miRNAs post-transcriptionally regulate gene expression. Prog Mol Subcell Biol, 50, 1-20.
26. Fassina A, Cappellesso R, Guzzardo V, et al (2012). Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol, 25, 86-99.
27. Feber A, Xi L, Luketich JD, et al (2008). MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg, 135, 255-60.
28. Feber A, Xi L, Pennathur A, et al (2011). MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg, 91, 1523-30.
29. Fletcher AM, Heaford AC, Trask DK (2008). Detection of metastatic head and neck squamous cell carcinoma using the relative expression of tissue-specific mir-205. Transl Oncol, 1, 202-8.
30. Gandellini P, Folini M, Longoni N, et al (2009). miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res, 69, 2287-95.
31. Gandellini P, Profumo V, Casamichele A, et al (2012). miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ, 19, 1750-60.
32. Ginos MA, Page GP, Michalowicz BS, et al (2004). Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res, 64, 55-63.
33. Gottardo F, Liu CG, Ferracin M, et al (2007). Micro-RNA profiling in kidney and bladder cancers. Urol Oncol, 25, 387-92.
34. Greene SB, Gunaratne PH, Hammond SM, Rosen JM (2010a). A putative role for microRNA-205 in mammary epithelial cell progenitors. J Cell Sci, 123, 606-18.
35. Greene SB, Herschkowitz JI, Rosen JM (2010b). The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biol, 7, 300-4.
36. Gregory PA, Bert AG, Paterson EL, et al (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol, 10, 593-601.
37. Gu J, Wang Y, Wu X (2013). MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des, 19, 1292-300.
38. Hagman Z, Haflidadóttir BS, Ceder JA, et al (2013). miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer, 108, 1668-76.
39. Hamamoto J, Soejima K, Yoda S, et al (2013). Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. Mol Med Rep, 8, 456-62.
40. Hesketh PJ, Clapp RW, Doos WG, Spechler SJ (1989). The increasing frequency of adenocarcinoma of the esophagus. Cancer, 64, 526-30.
41. Hiroki E, Akahira J, Suzuki F, et al (2010). Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci, 101, 241-9.
42. Iorio MV, Croce CM (2009). MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol, 27, 5848-56.
43. Iorio MV, Casalini P, Piovan C, et al (2009). microRNA-205 regulates HER3 in human breast cancer. Cancer Res, 69, 2195-200.
44. Iorio MV, Ferracin M, Liu CG, et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70.
45. Iorio MV, Visone R, Di Leva G, et al (2007). MicroRNA signatures in human ovarian cancer. Cancer Res, 67, 8699-707.
46. Jansson MD, Lund AH (2012). MicroRNA and cancer. Mol Oncol, 6, 590-610.
47. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
48. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.
49. Jiang J, Lee EJ, Gusev Y, Schmittgen TD (2005). Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res, 33, 5394-403.
50. Kalluri R, Weinberg RA (2009). The basics of epithelial-mesenchymal transition. J Clin Invest, 119, 1420-8.
51. Karaayvaz M, Zhang C, Liang S, Shroyer KR, Ju J (2012). Prognostic significance of miR-205 in endometrial cancer. PLoS One, 7, 35158.
52. Kimura S, Naganuma S, Susuki D, et al (2010). Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncol Rep, 23, 1625-33.
53. Kong D, Suzuki A, Zou TT, et al (1997). PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet, 17, 143-4.
54. Landgraf P, Rusu M, Sheridan R, et al (2007). A mammalian microRNA expression atlas based on small RNA library sequencing. Cell, 129, 1401-14.
55. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP (2003). Vertebrate microRNA genes. Science, 299, 1540.
56. Lu J, Getz G, Miska EA, et al (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834-8.
57. Majid S, Dar AA, Saini S, et al (2010). MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer, 116, 5637-49.
58. Majid S, Saini S, Dar AA, et al (2011). MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res, 71, 2611-21.
59. Matsushima K, Isomoto H, Kohno S, Nakao K (2010). MicroRNAs and esophageal squamous cell carcinoma. Digestion, 82, 138-44.
60. Matsushima K, Isomoto H, Yamaguchi N, et al (2011). MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med, 9, 30.
61. Mimeault M, Batra SK (2006). Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis, 27, 1-22.
62. Muratsu-Ikeda S, Nangaku M, Ikeda Y, et al (2012). Downregulation of miR-205 modulates cell susceptibility to oxidative and endoplasmic reticulum stresses in renal tubular cells. PLoS One, 7, 41462.
63. Neely LA, Rieger-Christ KM, Neto BS, et al (2010). A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol, 28, 39-48.
64. Pfaff J, Meister G (2013). Argonaute and GW182 proteins: an effective alliance in gene silencing. Biochem Soc Trans, 41, 855-60.
65. Piovan C, Palmieri D, Di Leva G, et al (2012). Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol, 6, 458-72.
66. Qu C, Liang Z, Huang J, et al (2012). miR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle, 11, 785-96.
67. Radojicic J, Zaravinos A, Vrekoussis T, et al (2011). MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle, 10, 507-17.
68. Ralfkiaer U HP, Bangsgaard N, Lovendorf MB, et al (2011). Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood, 118, 5891-900.
69. Ratner ES, Tuck D, Richter C, et al (2010). MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol, 118, 251-7.
70. Risinger JI, Hayes AK, Berchuck A, Barrett JC (1997). PTEN/MMAC1 mutations in endometrial cancers. Cancer Res, 57, 4736-8.
71. Saad R, Chen Z, Zhu S, et al (2013). Deciphering the unique microRNA signature in human esophageal adenocarcinoma. PLoS One, 8, 64463.
72. Said NA, Simpson KJ, Williams ED (2013). Strategies and challenges for systematically mapping biologically significant molecular pathways regulating carcinoma epithelial-mesenchymal transition. Cells Tissues Organs, 197, 424-34.
73. Savad S, Mehdipour P, Miryounesi M, et al (2012). Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran. Asian Pac J Cancer Prev, 13, 873-7.
74. Sempere LF, Christensen M, Silahtaroglu A, et al (2007). Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res, 67, 11612-20.
75. Sevignani C, Calin GA, Siracusa LD, Croce CM (2006). Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome, 17, 189-202.
76. Shah MA, Kurtz RC (2010). Upper gastrointestinal cancer predisposition syndromes. Hematol Oncol Clin North Am, 24, 815-35.
77. Shingara J, Keiger K, Shelton J, et al (2005). An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA, 11, 1461-70.
78. Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
79. Snowdon J, Zhang X, Childs T, Tron VA, Feilotter H (2011). The microRNA-200 family is upregulated in endometrial carcinoma. PLoS One, 6.
80. Solomides CC, Evans BJ, Navenot JM, et al (2012). MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis. Acta Cytol, 56, 645-4.
81. Song H, Bu G (2009). MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1. Biochem Biophys Res Commun, 388, 400-5.
82. Stang A, Pohlabeln H, Müller KM, et al (2006). Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer, 52, 29-36.
83. Su N, Qiu H, Chen Y, et al (2013). miR-205 promotes tumor proliferation and invasion through targeting ESRRG in endometrial carcinoma. Oncol Rep, 29, 2297-302.
84. Suzuki H, Maruyama R, Yamamoto E, Kai M(2012). DNA methylation and microRNA dysregulation in cancer. Mol Oncol, 6, 567-78.
85. Tashiro H, Blazes MS, Wu R, et al (1997). Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res, 57, 3935-40.
86. Tran MN, Choi W, Wszolek MF, et al (2013). The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem, 288, 3275-88.
87. Tran N, McLean T, Zhang X, et al (2007). MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun, 358, 12-7.
88. Verdoodt B, Neid M, Vogt M, et al (2013). MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int J Oncol, 43, 307-14.
89. Volinia S, Calin GA, Liu CG, et al (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A, 103, 2257-61.
90. Võsa U, Vooder T, Kolde R, et al (2013). Meta-analysis of microRNA expression in lung cancer. Int J Cancer, 132, 2884-93.
91. Wang D, Qiu C, Zhang H, et al (2010). Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PLoS One, 5, 13067.
92. Wang G, Chan ES, Kwan BC, et al (2012). Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer, 10, 106-13.
93. Wang WX, Wilfred BR, Hu Y, Stromberg AJ, Nelson PT (2010). "Anti-Argonaute RIP-Chip shows that miRNA transfections alter global patterns of mRNA recruitment to microribonucleoprotein complexes." RNA, 16, 394-404.
94. Wienholds E, Kloosterman WP, Miska E, et al (2005). MicroRNA expression in zebrafish embryonic development. Science, 309, 310-1.
95. Wiklund ED, Bramsen JB, Hulf T, et al (2011). Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer, 128, 1327-34.
96. Witten D, Tibshirani R, Gu SG, Fire A, Lui WO (2010). Ultra-high throughput sequencing-based small RNA discovery and discrete statistical biomarker analysis in a collection of cervical tumours and matched controls. BMC Biol, 8.
97. Wu H, Zhu S, Mo YY (2009). Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res, 19, 439-48.
98. Wu W, Lin Z, Zhuang Z, Liang X (2009). Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev, 18, 50-5.
99. Xie H, Zhao Y, Caramuta S, Larsson C, Lui WO (2012). miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS One, 7.
100. Xing L, Todd NW, Yu L, Fang H, Jiang F (2010). Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol, 23, 1157-64.
101. Xu Y, Brenn T, Brown ER, Doherty V, Melton DW (2012). Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br J Cancer, 106, 553-61.
102. Yanaihara N, Caplen N, Bowman E, et al (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9, 189-98.
103. Yu J, Ryan DG, Getsios S, et al (2008). MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. Proc Natl Acad Sci U S A, 105, 19300-5.
104. Yu L, Todd NW, Xing L, et al (2010). Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer, 127, 2870-8.
105. Zhang B, Pan X, Cobb GP, Anderson TA (2007). microRNAs as oncogenes and tumor suppressors. Dev Biol, 302, 1-12.
106. Zhu QC, Gao RY, Wu W, Qin HL (2013). Epithelial-mesenchymal Transition and Its Role in the Pathogenesis of Colorectal Cancer. Asian Pac J Cancer Prev, 14, 2689-98.
107. Zidar N, Boštjančič E, Gale N, et al (2011). Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck-hallmark of epithelial-mesenchymal transition. Hum Pathol, 42, 482-8.